Dietary Inulin to Improve SARS-CoV-2 Vaccine Response in Kidney Transplant Recipients: The RIVASTIM-Inulin Randomised Controlled Trial
Authors:
- Julian SingerJSJulian Singer
- Matthew J. TunbridgeMTMatthew J. Tunbridge
- Bree ShiBSBree Shi
- Griffith B. PerkinsGPGriffith B. Perkins
- Cheng Sheng ChaiCCCheng Sheng Chai
- Tania SalehiTSTania Salehi
- Beatrice Z. SimBSBeatrice Z. Sim
- Svjetlana KiretaSKSvjetlana Kireta
- Julie K. JohnstonJJJulie K. Johnston
- Anouschka AkermanAAAnouschka Akerman
- Vanessa MilogiannakisVMVanessa Milogiannakis
- Anupriya AggarwalAAAnupriya Aggarwal
Open Access
Abstract
Kidney transplant recipients are at an increased risk of hospitalisation and death from SARS-CoV-2 infection, and standard two-dose vaccination schedules are typically inadequate to generate protective immunity. Gut dysbiosis, which is common among kidney transplant recipients and known to effect systemic immunity, may be a contributing factor to a lack of vaccine immunogenicity in this at-risk cohort. The gut microbiota modulates vaccine responses, with the production of immunomodulatory short-chain fatty acids by bacteria such as Bifidobacterium associated with heightened vaccine responses in both observational and experimental studies. As SCFA-producing populations in the gut microbiota are enhanced by diets rich in non-digestible fibre, dietary supplementation with prebiotic fibre emerges as a potential adjuvant strategy to correct dysbiosis and improve vaccine-induced immunity. In a randomised, double-bind, placebo-controlled trial of 72 kidney transplant recipients, we found dietary supplementation with prebiotic inulin for 4 weeks before and after a third SARS-CoV2 mRNA vaccine to be feasible, tolerable, and safe. Inulin supplementation resulted in an increase in gut Bifidobacterium, as determined by 16S RNA sequencing, but did not increase in vitro neutralisation of live SARS-CoV-2 virus at 4 weeks following a third vaccination. Dietary fibre supplementation is a feasible strategy with the potential to enhance vaccine-induced immunity and warrants further investigation.Keywords
This publication has 72 references indexed in Scilit:
- Immune responses following 3rd and 4th doses of heterologous and homologous COVID-19 vaccines in kidney transplant recipientseClinicalMedicine, 2022
- Concurrent vaccination of kidney transplant recipients and close household cohabitants against COVID-19Kidney International, 2022
- A fourth SARS-CoV-2 mRNA vaccine in strictly seronegative kidney transplant recipientsKidney International, 2022
- The intestinal microbiota and improving the efficacy of COVID-19 vaccinationsJournal of Functional Foods, 2021
- Third dose of the BNT162b2 vaccine in heart transplant recipients: Immunogenicity and clinical experienceThe Journal of Heart and Lung Transplantation, 2021
- Antibody Response After a Third Dose of the mRNA-1273 SARS-CoV-2 Vaccine in Kidney Transplant Recipients With Minimal Serologic Response to 2 DosesJAMA, 2021
- Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant RecipientsJAMA, 2021
- Systematic Review and Meta-analysis of COVID-19 and Kidney Transplant Recipients, the South West London Kidney Transplant Network ExperienceKidney International Reports, 2021
- Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics supportJournal of Biomedical Informatics, 2009
- GSRS?A clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer diseaseDigestive Diseases and Sciences, 1988